Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
AssigneeCyclolab Cyclodextrin Research and Development Laboratory Ltd.
InventorsLajos Szente, István Puskas, Tamas Sohajda
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases. More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.
Claims4
A method for the treatment of Niemann Pick disease, which comprises administering an effective amount of a S-(carboxyalkyl)thio-cyclodextrin or a pharmaceutically applicable salt thereof to a patient in need thereof.
Dependencies are inferred from the claim text.